Federal Circuit Affirms Invalidity Of Toprol Patents
The U.S. Court of Appeals for the Federal Circuit agreed with the district court’s January ruling of invalidity, agreeing that the pharmaceutical giant's patents constituted double patenting. However, the Federal Circuit also vacated the lower court’s finding of inequitable conduct against AstraZeneca.
Generic drug maker Andrx Pharmaceuticals LLC, along with KV Pharmaceutical Co. and Eon...
To view the full article, register now.